
Lilly plans to launch at least three new medicines next year, senior managers announced during a meeting with analysts and …


A drug that once looked doomed to fail has shocked analysts by helping late-stage lung cancer patients live longer. Necitumumab …

Lilly posted a healthy set of financials at the end of July as the company looks to keep its growth …

Transition Therapeutics has bought Lilly’s early-stage osteoarthritis drug TT-601 that is designed to help patients with chronic bone pain. Transition …

Eli Lilly & Co is to run yet another trial of its Alzheimer’s drug solanezumab, which failed twice in Phase …

Women at risk of breast cancer can now be offered a daily pill on the NHS to stop the disease …

New clinical trial results have shown Lilly’s investigational type 2 diabetes drug has beaten its three nearest rivals in reducing …

Eli Lilly is to take up its option to develop and commercialise a type 2 diabetes candidate, paying Canadian firm …

Lilly is sponsoring Olympic hurdler Colin Jackson’s ‘Go Dad Run’, a new 5k run for men to raise awareness of …

Boehringer Ingelheim and Eli Lilly have launched an educational digital game for type 2 diabetes called Complications Combat. The game …

Eli Lilly and Roche Diagnostics are among the key backers of a $360 million US life sciences research facility which …
Takeda and Lundbeck’s treatment for major depressive disorder has demonstrated a significant improvement in patients’ symptoms during trials. Brintellix (Vortioxetine) …

Eli Lilly has taken a $30 million hit after abandoning late-stage development of its investigational cancer drug enzastaurin. The compound …

Loss of exclusivity on Lilly’s blockbuster antipsychotic Zyprexa in 2011 continued to hit the company hard in the first quarter …